EUVIMEDEUVIMED entdecken
Crossref

Clinical advances in later-line therapy for metastatic or refractory colorectal cancer

Li Ma, Xia Liu, Ying Zhang, Yong Luo

World Journal of Gastroenterology · 14.01.2027 · 33 (2)

DOI: 10.3748/wjg.123996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 14.01.2027. Verfasst von Li Ma und 3 weiteren Autor:innen. Die Arbeit nennt 124 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic colorectal cancer still ranks among the leading causes of cancer-related death globally owing to its poor treatment response. For patients with progression after first-line therapy, especially those with microsatellite-stable/proficient mismatch repair tumors or tumors harboring BRAF V600E or KRAS G12C mutations, high-quality evidence for optimal therapies remains scarce. This review summarizes clinical studies from the past 5 years on second-line and subsequent therapies for metastatic colorectal cancer, covering optimized combinations of chemotherapy, targeted therapy, immunotherapy, and radiotherapy, along with evaluations of novel agents. A review of these clinical advances reveals that chemotherapy regimens based on raltitrexed or trifluridine/tipiracil hydrochloride mixture (TAS-102) have demonstrated favorable efficacy in patients with fluoropyrimidine resistance. Antiangiogenic agents, epidermal growth factor receptor/human epidermal growth factor receptor 2/mesenchymal-epithelial transition factor blockade, BRAF inhibitors, and KRAS G12C inhibitors prolong survival. Immunotherapy yields durable responses in microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer, especially with dual immune checkpoint inhibition. Combinations of drugs with different mechanisms of action may treat refractory microsatellite-stable/proficient mismatch repair disease. Novel antibody-drug conjugates and other antitumor agents offer new options for previously treated patients. Limited high-quality evidence hinders optimal regimen selection. Future work should focus on improving individualized therapy and multidisciplinary management.

Zitieren

APA

Ma, L., Liu, X., Zhang, Y., & Luo, Y. (2027). Clinical advances in later-line therapy for metastatic or refractory colorectal cancer. World Journal of Gastroenterology, 33(2). https://doi.org/10.3748/wjg.123996

Vancouver

Ma L, Liu X, Zhang Y, Luo Y. Clinical advances in later-line therapy for metastatic or refractory colorectal cancer. World Journal of Gastroenterology. 2027;33(2). doi:10.3748/wjg.123996

BibTeX
@article{Ma2027,
  author = {Ma, Li and Liu, Xia and Zhang, Ying and Luo, Yong},
  title = {Clinical advances in later-line therapy for metastatic or refractory colorectal cancer},
  journal = {World Journal of Gastroenterology},
  year = {2027},
  volume = {33},
  number = {2},
  doi = {10.3748/wjg.123996}
}
Kostenlos starten →